These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dysbiosis of oropharyngeal microbiome and antibiotic resistance in hospitalized COVID-19 patients. Wu J; Liu W; Zhu L; Li N; Luo G; Gu M; Peng M; Zeng S; Wu S; Zhang S; Chen Q; Cai M; Cao W; Jiang Y; Luo C; Tian D; Shi M; Shu Y; Chang G; Luo H J Med Virol; 2023 Apr; 95(4):e28727. PubMed ID: 37185870 [TBL] [Abstract][Full Text] [Related]
4. Temporal dynamics of oropharyngeal microbiome among SARS-CoV-2 patients reveals continued dysbiosis even after Viral Clearance. Paine SK; Rout UK; Bhattacharyya C; Parai D; Alam M; Nanda RR; Tripathi D; Choudhury P; Kundu CN; Pati S; Bhattacharya D; Basu A NPJ Biofilms Microbiomes; 2022 Aug; 8(1):67. PubMed ID: 36002454 [TBL] [Abstract][Full Text] [Related]
5. The Relationship Between Pediatric Gut Microbiota and SARS-CoV-2 Infection. Romani L; Del Chierico F; Macari G; Pane S; Ristori MV; Guarrasi V; Gardini S; Pascucci GR; Cotugno N; Perno CF; Rossi P; Villani A; Bernardi S; Campana A; Palma P; Putignani L; Front Cell Infect Microbiol; 2022; 12():908492. PubMed ID: 35873161 [TBL] [Abstract][Full Text] [Related]
6. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Zuo T; Zhang F; Lui GCY; Yeoh YK; Li AYL; Zhan H; Wan Y; Chung ACK; Cheung CP; Chen N; Lai CKC; Chen Z; Tso EYK; Fung KSC; Chan V; Ling L; Joynt G; Hui DSC; Chan FKL; Chan PKS; Ng SC Gastroenterology; 2020 Sep; 159(3):944-955.e8. PubMed ID: 32442562 [TBL] [Abstract][Full Text] [Related]
7. Metatranscriptomic analysis revealed Lu S; Zhou Y; Hu Y; Wang J; Li H; Lin Y; Wang D; Xian J; Zhao S; Ma J; Zhu Z; Yang S; Meng Q; Kang Y; Chen B; Li W Front Cell Infect Microbiol; 2023; 13():1161763. PubMed ID: 37333851 [TBL] [Abstract][Full Text] [Related]
8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
9. Metatranscriptomic Analysis Reveals Disordered Alterations in Oropharyngeal Microbiome during the Infection and Clearance Processes of SARS-CoV-2: A Warning for Secondary Infections. Zhou Y; Lu S; Wei X; Hu Y; Li H; Wang J; Lin Y; Li M; Wang M; Ma J; Zhu Z; Yang S; Ying B; Zhang W; Chen B; Li W Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671391 [TBL] [Abstract][Full Text] [Related]
10. Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients. de Castilhos J; Zamir E; Hippchen T; Rohrbach R; Schmidt S; Hengler S; Schumacher H; Neubauer M; Kunz S; Müller-Esch T; Hiergeist A; Gessner A; Khalid D; Gaiser R; Cullin N; Papagiannarou SM; Beuthien-Baumann B; Krämer A; Bartenschlager R; Jäger D; Müller M; Herth F; Duerschmied D; Schneider J; Schmid RM; Eberhardt JF; Khodamoradi Y; Vehreschild MJGT; Teufel A; Ebert MP; Hau P; Salzberger B; Schnitzler P; Poeck H; Elinav E; Merle U; Stein-Thoeringer CK Clin Infect Dis; 2022 Aug; 75(1):185. PubMed ID: 35536665 [No Abstract] [Full Text] [Related]
11. The impact of infection with COVID-19 on the respiratory microbiome: A narrative review. Zhu T; Jin J; Chen M; Chen Y Virulence; 2022 Dec; 13(1):1076-1087. PubMed ID: 35763685 [TBL] [Abstract][Full Text] [Related]
12. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662 [TBL] [Abstract][Full Text] [Related]
13. The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract. Xie L; Luo G; Yang Z; Wu WC; Chen J; Ren Y; Zeng Z; Ye G; Pan Y; Zhao WJ; Chen YQ; Hou W; Sun Y; Guo D; Yang Z; Li J; Holmes EC; Li Y; Chen L; Shi M J Infect; 2024 Mar; 88(3):106118. PubMed ID: 38342382 [TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
15. Autoimmunity and COVID-19 - The microbiotal connection. Katz-Agranov N; Zandman-Goddard G Autoimmun Rev; 2021 Aug; 20(8):102865. PubMed ID: 34118455 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome. Rosas-Salazar C; Kimura KS; Shilts MH; Strickland BA; Freeman MH; Wessinger BC; Gupta V; Brown HM; Rajagopala SV; Turner JH; Das SR J Allergy Clin Immunol; 2021 Apr; 147(4):1226-1233.e2. PubMed ID: 33577896 [TBL] [Abstract][Full Text] [Related]
20. Oropharyngeal microbial ecosystem perturbations influence the risk for acute respiratory infections in common variable immunodeficiency. Pulvirenti F; Giufrè M; Pentimalli TM; Camilli R; Milito C; Villa A; Sculco E; Cerquetti M; Pantosti A; Quinti I Front Immunol; 2024; 15():1371118. PubMed ID: 38873612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]